Journal
CELLULAR IMMUNOLOGY
Volume 276, Issue 1-2, Pages 67-74Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.cellimm.2012.03.010
Keywords
Cyclophosphamide; Chemotherapy; Dendritic cells; Lymphocytes; Regulatory T cells; Natural killer cells; Blood; Bone marrow; Spleen
Categories
Funding
- NCI NIH HHS [R01 CA083672] Funding Source: Medline
Ask authors/readers for more resources
Recently, we showed that post cyclophosphamide (CTX) microenvironment benefits the function of transferred T cells. Analysis of the kinetics of cellular recovery after CTX treatment showed that a single 4 mg/mouse CTX treatment decreased the absolute number of leukocytes in the peripheral blood (PBL) at days 3-15, and in the spleen and bone marrow (BM) at days 3-6. The absolute numbers of CD11c(+)cD11b(-) and CD11c(+)cD11b(+) dendritic cells (DCs), CD11b(+) and Ly6G(+) myeloid cells. T and B cells, CD4(+)CD25(+) T regulatory (T-reg) cells, and NK1.1(+) cells also decreased. The cell numbers returned to control levels during the recovery phase. The absolute numbers of B cells remained low for 3 weeks. The numbers of DCs increased in PBL and spleen at day 9 but returned to control levels at day 15. These data indicate that CTX alters the cellular microenvironment in kinetics that might be precisely targeted to benefit the host. (C) 2012 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available